Covered recipient · General Payments record
GREGORY J FELDMAN
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$14,199.78
181 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,153.60 | 8 |
| Consulting Fee | $4,260.00 | 2 |
| Food and Beverage | $2,786.18 | 171 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GREGORY J FELDMAN
NPI 1710942305 · CMS profile ID 214078
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
COLUMBIA, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- GREGORY J FELDMAN, NPI 1710942305, CMS profile ID 214078, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1710942305?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
181 matching records · $14,199.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 181.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Electromed, Inc. | $21.29 | 09/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602301 | CMS |
| Philips Electronics North America Corporation | $12.72 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853235917 | CMS |
| Grifols USA, LLC | $13.64 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846771787 | CMS |
| Janssen Pharmaceuticals, Inc | $11.65 | 09/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788600417 | CMS |
| Mylan Inc. | $1,861.00 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965336653 | CMS |
| Mylan Inc. | $986.00 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965336655 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5.77 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763342994 | CMS |
| Electromed, Inc. | $6.01 | 08/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602259 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.09 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829579547 | CMS |
| Philips Electronics North America Corporation | $11.94 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 853235915 | CMS |
| Electromed, Inc. | $19.17 | 08/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602227 | CMS |
| Actelion Pharmaceuticals US, Inc. | $18.32 | 08/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788600423 | CMS |
| Nabriva Therapeutics, plc | $20.61 | 08/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 844883935 | CMS |
| Paratek Pharmaceuticals, Inc. | $14.86 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 813502115 | CMS |
| Mylan Specialty L.P. | $15.85 | 08/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965427109 | CMS |
| GlaxoSmithKline, LLC. | $10.09 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802988743 | CMS |
| Novartis Pharmaceuticals Corporation | $15.51 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812676201 | CMS |
| Mylan Specialty L.P. | $13.96 | 08/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965425975 | CMS |
| Paratek Pharmaceuticals, Inc. | $14.19 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 813502111 | CMS |
| GlaxoSmithKline, LLC. | $12.44 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802943823 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.75 | 07/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819924325 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.42 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763342996 | CMS |
| Actelion Pharmaceuticals US, Inc. | $21.73 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788600427 | CMS |
| GlaxoSmithKline, LLC. | $12.33 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802952869 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.30 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829495025 | CMS |
| Electromed, Inc. | $21.90 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602117 | CMS |
| GlaxoSmithKline, LLC. | $14.10 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802209199 | CMS |
| Electromed, Inc. | $26.22 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602087 | CMS |
| GlaxoSmithKline, LLC. | $11.84 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801991055 | CMS |
| Janssen Pharmaceuticals, Inc | $16.40 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788600411 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.39 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829765311 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.82 | 07/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763342998 | CMS |
| GlaxoSmithKline, LLC. | $13.34 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 801687109 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.22 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763343000 | CMS |
| Janssen Pharmaceuticals, Inc | $8.73 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788600409 | CMS |
| Electromed, Inc. | $27.68 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849602031 | CMS |
| GENZYME CORPORATION | $15.59 | 06/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843432781 | CMS |
| GENZYME CORPORATION | $11.63 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843432761 | CMS |
| Mylan Specialty L.P. | $21.24 | 06/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965420343 | CMS |
| GlaxoSmithKline, LLC. | $12.27 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803026745 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.33 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819924323 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.34 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829883023 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12.55 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763343002 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.04 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829556025 | CMS |
| Electromed, Inc. | $21.31 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849601967 | CMS |
| Genentech USA, Inc. | $24.34 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835916017 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.34 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829393323 | CMS |
| GlaxoSmithKline, LLC. | $10.39 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 803055151 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.72 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829992915 | CMS |
| Mylan Specialty L.P. | $15.92 | 06/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965418471 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $542,548.17 | 46 |
| PY2024 | Principal investigator | $1,496,878.67 | 75 |
| PY2023 | Recipient | $12,662.49 | 5 |
| PY2023 | Principal investigator | $2,345,387.83 | 1,780 |
| PY2022 | Recipient | $8,394.00 | 1 |
| PY2022 | Principal investigator | $5,905,879.41 | 978 |
| PY2021 | Recipient | $3,316.83 | 3 |
| PY2021 | Principal investigator | $2,559,241.44 | 88 |
| PY2020 | Recipient | $14,625.26 | 2 |
| PY2020 | Principal investigator | $459,066.41 | 46 |
| PY2019 | Recipient | $189.08 | 1 |
| PY2019 | Principal investigator | $1,745,418.86 | 213 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
46 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Verona Pharma, Inc. | $30,753.12 | 12/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891567 |
| Principal investigator 1 | PFIZER INC. | $172.50 | 12/16/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228734005 |
| Principal investigator 1 | Verona Pharma, Inc. | $61,933.28 | 11/19/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891565 |
| Principal investigator 1 | Verona Pharma, Inc. | $883.20 | 11/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891589 |
| Principal investigator 1 | Verona Pharma, Inc. | $82.80 | 11/14/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891591 |
| Principal investigator 1 | Verona Pharma, Inc. | $10,000.00 | 11/12/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891611 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,852.00 | 11/12/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891613 |
| Principal investigator 1 | PFIZER INC. | $3,051.00 | 10/23/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228733266 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,200.00 | 09/17/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891521 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,406.00 | 09/03/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130638 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,200.00 | 08/27/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891515 |
| Principal investigator 1 | Verona Pharma, Inc. | $3,000.00 | 08/20/2025 | Non-covered Recipient Entity MONROE BIOMEDICAL RESEARCH | A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | No dispute reported | 06/30/2026 | 1232891429 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,311.00 | 08/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130603 |
| Principal investigator 1 | ModernaTX, Inc. | $12,720.00 | 07/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007964 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,063.50 | 07/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130476 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $3,693.30 | 06/24/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717954 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $3,110.25 | 06/13/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717609 |
| Principal investigator 1 | ModernaTX, Inc. | $89,680.00 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007938 |
| Principal investigator 1 | ModernaTX, Inc. | $334.00 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007942 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,493.50 | 06/09/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130400 |
| Principal investigator 1 | ModernaTX, Inc. | $160.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007954 |
| Principal investigator 1 | ModernaTX, Inc. | $22,400.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007958 |
| Principal investigator 1 | ModernaTX, Inc. | $1,815.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007960 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,000.00 | 06/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185546359 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $412.59 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase II Randomized Double-blind Placebo controlled Study to Assess the Efficacy Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis FRONTIER 4 | No dispute reported | 06/30/2026 | 1185546361 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $7,901.73 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717881 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $203.00 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226130396 |
| Principal investigator 1 | ModernaTX, Inc. | $334.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007946 |
| Principal investigator 1 | ModernaTX, Inc. | $152,000.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007956 |
| Principal investigator 1 | ModernaTX, Inc. | $1,045.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007944 |
| Principal investigator 1 | ModernaTX, Inc. | $3,325.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007962 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $14,963.20 | 03/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717409 |
| Principal investigator 1 | PFIZER INC. | $36,060.00 | 03/05/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228796406 |
| Principal investigator 1 | ModernaTX, Inc. | $668.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007940 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $481.00 | 02/06/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717221 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $962.00 | 01/30/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242717197 |
| Principal investigator 1 | ModernaTX, Inc. | $1,372.80 | 01/29/2025 | Non-covered Recipient Entity KEYSTONE RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252980920 |
| Principal investigator 1 | ModernaTX, Inc. | $4,358.90 | 01/29/2025 | Non-covered Recipient Entity KEYSTONE RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252980922 |
| Principal investigator 1 | Eli Lilly and Company | $10,294.00 | 01/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187892622 |
| Principal investigator 1 | ModernaTX, Inc. | $6,270.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007948 |
| Principal investigator 1 | ModernaTX, Inc. | $1,520.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007950 |
| Principal investigator 1 | ModernaTX, Inc. | $2,004.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253007952 |
| Principal investigator 1 | ModernaTX, Inc. | $12,468.30 | 01/24/2025 | Non-covered Recipient Entity KEYSTONE RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252980918 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 01/15/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228800096 |
| Principal investigator 1 | Eli Lilly and Company | $52.70 | 01/09/2025 | Non-covered Recipient Entity KEYSTONE RESEARCH LLC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187886244 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,537.50 | 01/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase III Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma | No dispute reported | 06/30/2026 | 1185546357 |